MicroRNAs and prostate cancer: From preclinical research to translational oncology

Marcello Maugeri-Saccà, Valeria Coppola, Désirée Bonci, Ruggero De Maria

Research output: Contribution to journalArticlepeer-review


The management of prostate cancer patients is rapidly changing. The extended survival seen in randomized phase III trials with new molecules has significantly enriched the therapeutic armamentarium, and ongoing clinical trials are assessing whether the integration of these active drugs within established therapeutic regimens results in a further benefit for patients. This complex scenario is raising the need for the identification and validation of biomarkers able to drive the decision-making process during the course of the disease. Compelling evidence has documented the role of microRNAs in cancer biology, and their multifaceted biological activity makes them an attractive candidate as diagnostic, prognostic, and predictive biomarkers. This review summarizes the current knowledge about microRNA deregulation in prostate cancer, how these molecules have been investigated in the clinical setting, and strategies investigators should consider for sharpening their potential.

Original languageEnglish
Pages (from-to)253-261
Number of pages9
JournalCancer Journal (United States)
Issue number3
Publication statusPublished - May 2012


  • biomarkers
  • microRNAs
  • prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'MicroRNAs and prostate cancer: From preclinical research to translational oncology'. Together they form a unique fingerprint.

Cite this